Cigna and Oscar health are expanding the reach of their cobranded health plan. (Getty/michaelquirk)
Cigna and Oscar Health are expanding access to their cobranded health plan to more regions in California.
When the two insurers unveiled their Cigna + Oscar plans which target small businesses last summer, the plans were initially available in Atlanta, Tennessee and select California counties, namely the San Francisco bay area.
The plan s reach will grow to include the Bay Area, Central Coast, Greater Sacramento, Inland Empire, Los Angeles, Orange County, North Bay, and San Diego regions, the companies announced Thursday.
“Small businesses are the heart of the economy, and of their local communities. Now more than ever, they need affordable health insurance that works for them and their employees,” said Bruce Grimm, Cigna s senior vice president of segments, in a statement.
To embed, copy and paste the code into your website or blog:
By now we should all be well-schooled in the various types and sources of fraud claims, as well as the dangers of undefined fraud carve-outs to the sell-side in an M&A transaction governed by Delaware law. But a recent decision by the Delaware Supreme Court,
Express Scripts, Inc. v. Bracket Holdings Corp., 2021 WL 752744 (Del. Feb. 23, 2021), provides an opportunity to reaffirm that prior schooling and ensure, for the sell-side, that fraud carve-outs only encompass deliberate lying by the seller itself respecting the negotiated contractual representations set forth in the written acquisition agreement.
Share this article
Share this article
EXTON, Pa., Feb. 17, 2021 /PRNewswire/ Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis Cosentyx and Eli Lilly s Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherix s
RealTime Dynamix
™ service, the official entrance of the IL-17 inhibitors is causing a shift in the market where UCB s Cimzia previously held the position as the only biologic with commercial availability.
The report, which highlights the differences in referral, diagnostic, and management patterns of ankylosing spondylitis (AS) and nr-axSpA patients, found that the incidence of biologic/JAK treatment (including off-label use) remains higher in AS than it does in nr-axSpA. However, biologic treatment in moderate and severe forms of nr-axSpA has seen growth over the last few years, owin
Progress while adjusting to new market dynamics
From a management perspective, the most important factor for success is to be an agile company, ready to accelerate development and to capture opportunities when they arise, but also be prepared to shift priorities when the market requires it. The quarter has seen progress on many fronts, with US Pharma showing net revenue growth in local currency comparing to last quarter and improved EBIT margin, Digital Therapeutics (DTx) testing new reimbursement routes and launching new commercialization concepts. Our lead pipeline project, a rescue medication for opioid overdose, OX124, received positive feedback from the FDA on the IND application enabling a request for Fast Track Designation of the product and we also reported an exclusive license and supply agreement for ZUBSOLV® in Europe.